Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $6.8 million.

  • Kymera Therapeutics' Other Non-Current Assets rose 1807.02% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 1807.02%. This contributed to the annual value of $5.8 million for FY2024, which is 29.25% down from last year.
  • As of Q3 2025, Kymera Therapeutics' Other Non-Current Assets stood at $6.8 million, which was up 1807.02% from $5.8 million recorded in Q2 2025.
  • Kymera Therapeutics' 5-year Other Non-Current Assets high stood at $6.8 million for Q3 2025, and its period low was $1.6 million during Q2 2021.
  • In the last 5 years, Kymera Therapeutics' Other Non-Current Assets had a median value of $5.8 million in 2025 and averaged $5.3 million.
  • Within the past 5 years, the most significant YoY rise in Kymera Therapeutics' Other Non-Current Assets was 69899.5% (2021), while the steepest drop was 1117.94% (2021).
  • Quarter analysis of 5 years shows Kymera Therapeutics' Other Non-Current Assets stood at $6.1 million in 2021, then increased by 0.23% to $6.1 million in 2022, then dropped by 5.2% to $5.8 million in 2023, then fell by 0.29% to $5.8 million in 2024, then rose by 17.85% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $5.8 million for Q2 2025, and $5.8 million during Q1 2025.